Systemic toxicities of trastuzumab‐emtansine predict tumor response in HER2 + metastatic breast cancer-Reference-Cited by-同舟云学术

Systemic toxicities of trastuzumab‐emtansine predict tumor response in HER2 + metastatic breast cancer

Published:2021-05-06 Issue: Volume: Page:
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Tang Shou‐Ching¹^ORCID,Capra Carter L.²,Ajebo Germame H.³,Meza‐Junco Judith⁴,Mairs Simon⁴,Craft Barbara S.¹,Zhu Xiaofu⁴,Maihle Nita¹,Hillegass William B.⁵

Affiliation:

1. Cancer Center and Research Institute University of Mississippi Medical Center Jackson Mississippi USA

2. Alabama Oncology Birmingham Alabama USA

3. Department of Medicine, Division of Hematology/Oncology Georgia Cancer Center, Augusta University Augusta Georgia USA

4. Division of Medical Oncology Cross Cancer Institute, University of Alberta Edmonton Alberta Canada

5. Departments of Medicine and Data Science University of Mississippi Medical Center Jackson Mississippi USA

Funder

Agencia de Innovación y Desarrollo de Andalucía

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ijc.33597

Reference34 articles.

1. Cancer statistics, 2019;Siegel RL;CA Cancer J Clin,2019

2. Amplification of a novel v‐erbB‐related gene in a human mammary carcinoma;King CR;Science,1985

3. Human breast cancer: correlation of relapse and survival with amplification of the HER‐2/neu oncogene;Slamon DJ;Science,1987

4. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional‐based review;Dawood S;J Clin Oncol,2010

5. Multinational study of the efficacy and safety of humanized anti‐HER2 monoclonal antibody in women who have HER2‐overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease;Cobleigh MA;J Clin Oncol,1999

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Early thrombocytopenia predicts longer time‑to‑treatment discontinuation in trastuzumab emtansine treatment;Oncology Letters;2023-10-23

2. Targeting human EGFR 2 (HER2) in salivary gland carcinoma;Expert Review of Anticancer Therapy;2023-05-16

3. Acute thrombocytopenia induced by trastuzumab due to complement reaction: A case report;Frontiers in Medicine;2022-12-06

4. Anti-HER2 therapy in metastatic breast cancer: many choices and future directions;Cancer and Metastasis Reviews;2022-02-10